Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stryphnodendron adstringens is a tree native to Brazil and commonly known as "barbatimão." The stem bark is widely used in traditional medicine for its wound-healing, anti-inflammatory, antimicrobial, and astringent properties. Its pharmacological effects are attributed to high levels of tannins and polyphenols such as gallic acid and catechins (including epigallocatechin gallate), as well as other flavonoids like quercetin and kaempferol. Extracts from the bark have demonstrated immunomodulatory activity by reducing pro-inflammatory cytokine expression in vitro. Additional reported activities include antiprotozoal, hypoglycemic, antiviral effects, antioxidant properties, and potential anticancer activity. Formulations using the extract have been developed for topical use in wound healing[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stryphnodendron adstringens.